Cargando…
Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasin...
Autores principales: | Lambertini, Matteo, Richard, François, Nguyen, Bastien, Viglietti, Giulia, Villarreal-Garza, Cynthia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410390/ https://www.ncbi.nlm.nih.gov/pubmed/30886529 http://dx.doi.org/10.1177/1179558119828393 |
Ejemplares similares
-
Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
por: Massarotti, C., et al.
Publicado: (2023) -
The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021) -
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018) -
Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin‐releasing hormone agonist for women undergoing fertility preservation
por: Hong, Yeon Hee, et al.
Publicado: (2022) -
Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)